Geographic atrophy shows up as light patches in the back of your eye. Visual acuity test . You’ll look at a reading chart to measure how many letters you can see clearly from a distance.

Carl D. Regillo, MD, spoke with Healio about the use of complement blockers in geographic atrophy.

Geographic atrophy is a complex disease, and there’s still a lot we don’t know about what causes it and how best to treat it. But we may see a number of exciting new therapies within the next ...

UK start-up Complement Therapeutics has raised an impressive €72 million ($79 million) in first-round financing that will be used to take a gene therapy for sight-robbing disease geographic ...

- Geographic atrophy (GA) program introduced with complement Factor I (CFI), a key component of the complement cascade, as a payload and utilizing two intravitreal (IVT) capsids, 7m8 and LSV1 ...

Pegcetacoplan, an investigational complement factor inhibitor that has the potential to be the first FDA–approved treatment for geographic atrophy in dry age-related macular degeneration (AMD ...

Novartis has confirmed it will discontinue development of a gene therapy for sight-robbing disease geographic atrophy ... GT005 aimed to treat GA by delivering the gene for complement factor ...

Geographic atrophy disease progression is explored by a panel of medical experts. ... We have several gene mutations in complement factor H, ... Another social factor is smoking.

Ophthalmologists are cautious about prescribing the current geographic atrophy (GA) treatment options Syfovre and Izervay, introduced in 2023 as the first-ever therapy for GA, according to Spherix ...

Two treatments for geographic atrophy, Syfovre and Izervay, were approved in 2023. Learn how they work and whether you’re a candidate for using them.

Complement Therapeutics GmbH raised €72 million (US$79.4 million) in a series A round to move into the clinic a novel gene therapy for treating geographic atrophy secondary to dry age-related macular ...